- Home
- FYBR vs RVMD Comparison
FYBR vs RVMD Comparison
Compare FYBR & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FYBR
- RVMD
- Stock Information
- Founded
- FYBR 1935
- RVMD 2014
- Country
- FYBR United States
- RVMD United States
- Employees
- FYBR N/A
- RVMD N/A
- Industry
- FYBR Telecommunications Equipment
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FYBR Consumer Discretionary
- RVMD Health Care
- Exchange
- FYBR Nasdaq
- RVMD Nasdaq
- Market Cap
- FYBR 9.2B
- RVMD 7.4B
- IPO Year
- FYBR N/A
- RVMD 2020
- Fundamental
- Price
- FYBR $36.18
- RVMD $39.66
- Analyst Decision
- FYBR Buy
- RVMD Strong Buy
- Analyst Count
- FYBR 9
- RVMD 12
- Target Price
- FYBR $35.33
- RVMD $68.67
- AVG Volume (30 Days)
- FYBR 4.0M
- RVMD 1.7M
- Earning Date
- FYBR 08-01-2025
- RVMD 08-06-2025
- Dividend Yield
- FYBR N/A
- RVMD N/A
- EPS Growth
- FYBR N/A
- RVMD N/A
- EPS
- FYBR N/A
- RVMD N/A
- Revenue
- FYBR $5,986,000,000.00
- RVMD N/A
- Revenue This Year
- FYBR $4.51
- RVMD N/A
- Revenue Next Year
- FYBR $3.34
- RVMD $241.39
- P/E Ratio
- FYBR N/A
- RVMD N/A
- Revenue Growth
- FYBR 3.69
- RVMD N/A
- 52 Week Low
- FYBR $24.43
- RVMD $29.17
- 52 Week High
- FYBR $39.21
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- FYBR 42.64
- RVMD 49.08
- Support Level
- FYBR $36.04
- RVMD $38.57
- Resistance Level
- FYBR $36.30
- RVMD $42.40
- Average True Range (ATR)
- FYBR 0.13
- RVMD 1.38
- MACD
- FYBR -0.02
- RVMD -0.16
- Stochastic Oscillator
- FYBR 34.15
- RVMD 28.46
About FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.